Minimally Invasive Surgical (MIS) Devices:Medical Devices Pipeline Assessment 2016



Wise.Guy.

Minimally Invasive Surgical (MIS) Devices Medical Devices Pipeline Assessment, 2016

PUNE, INDIA, November 16, 2016 /EINPresswire.com/ — The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Minimally Invasive Surgical (MIS) Devices pipeline products.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/729487-minimally-invasive-surgical-mis-devices-medical-devices-pipeline-assessment-2016

Scope
– Extensive coverage of the Minimally Invasive Surgical (MIS) Devices under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of Minimally Invasive Surgical (MIS) Devices and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment / industry

The report enables you to –
– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of Minimally Invasive Surgical (MIS) Devices under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 9
2.1 Minimally Invasive Surgical (MIS) Devices Overview 9
3 Products under Development 10
3.1 Minimally Invasive Surgical (MIS) Devices – Pipeline Products by Stage of Development 10
3.2 Minimally Invasive Surgical (MIS) Devices – Pipeline Products by Territory 11
3.3 Minimally Invasive Surgical (MIS) Devices – Pipeline Products by Regulatory Path 12
3.4 Minimally Invasive Surgical (MIS) Devices – Pipeline Products by Estimated Approval Date 13
3.5 Minimally Invasive Surgical (MIS) Devices – Ongoing Clinical Trials 14
4 Minimally Invasive Surgical (MIS) Devices – Pipeline Products under Development by Companies 15
4.1 Minimally Invasive Surgical (MIS) Devices Companies – Pipeline Products by Stage of Development 15
4.2 Minimally Invasive Surgical (MIS) Devices – Pipeline Products by Stage of Development 17
5 Minimally Invasive Surgical (MIS) Devices Companies and Product Overview 18
5.1 Actuated Medical, Inc. Company Overview 18
5.1.1 Actuated Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18
5.2 BriteSeed Company Overview 20
5.2.1 BriteSeed Pipeline Products & Ongoing Clinical Trials Overview 20
5.3 Delft University of Technology Company Overview 21
5.3.1 Delft University of Technology Pipeline Products & Ongoing Clinical Trials Overview 21
5.4 DistalMotion Company Overview 24
5.4.1 DistalMotion Pipeline Products & Ongoing Clinical Trials Overview 24
5.5 ES Vascular Ltd. Company Overview 26
5.5.1 ES Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview 26
5.6 Ethicon Endo-Surgery, Inc. Company Overview 27
5.6.1 Ethicon Endo-Surgery, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27
5.7 Eximis Company Overview 28
5.7.1 Eximis Pipeline Products & Ongoing Clinical Trials Overview 28
5.8 FlexDex Company Overview 29
5.8.1 FlexDex Pipeline Products & Ongoing Clinical Trials Overview 29
5.9 Fortimedix B.V. Company Overview 31
5.9.1 Fortimedix B.V. Pipeline Products & Ongoing Clinical Trials Overview 31
5.10 Hadassah Medical Center Company Overview 32
5.10.1 Hadassah Medical Center Pipeline Products & Ongoing Clinical Trials Overview 32
5.11 Human Extensions LTD Company Overview 33
5.11.1 Human Extensions LTD Pipeline Products & Ongoing Clinical Trials Overview 33
5.12 Imperial College London Company Overview 34
5.12.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 34
5.13 John Hopkins University Company Overview 35
5.13.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 35
5.14 Osaka University Company Overview 36
5.14.1 Osaka University Pipeline Products & Ongoing Clinical Trials Overview 36
5.15 Rambam Health Care Campus Company Overview 37
5.15.1 Rambam Health Care Campus Pipeline Products & Ongoing Clinical Trials Overview 37
5.16 Signum Surgical Ltd Company Overview 38
5.16.1 Signum Surgical Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
5.17 Technische Universiteit Eindhoven Company Overview 39
5.17.1 Technische Universiteit Eindhoven Pipeline Products & Ongoing Clinical Trials Overview 39
5.18 UltraSurge Technologies Ltd. Company Overview 40
5.18.1 UltraSurge Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 40
5.19 University of California, San Francisco Company Overview 41
5.19.1 University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview 41
5.20 University of Wisconsin Madison Company Overview 45
5.20.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 45
5.21 Varada Innovations Inc. Company Overview 47
5.21.1 Varada Innovations Inc. Pipeline Products & Ongoing Clinical Trials Overview 47
5.22 VenX Medical LLC Company Overview 48
5.22.1 VenX Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 48
5.23 XACT Robotics Ltd. Company Overview 51
5.23.1 XACT Robotics Ltd. Pipeline Products & Ongoing Clinical Trials Overview 51
6 Minimally Invasive Surgical (MIS) Devices- Recent Developments 52
6.1 Oct 26, 2016: LeMaitre Q3 2016 Record Sales $23.2 mm (+22%), Record Op. Income $5.3 mm (+61%) 52
6.2 Oct 26, 2016: Life Spine Achieves 32% Sales Growth and Announces Industry’s Largest Post-Packing Capabilities for Lateral Fusion 52
6.3 Oct 18, 2016: Intuitive Surgical Announces Third Quarter Earnings 53
6.4 Oct 17, 2016: Fortimedix Surgical Announces the U.S. Launch of symphonX Surgical Platform, the World’s Lowest Profile Single-Port Surgery Solution, During American College of Surgeons Clinical Congress 2016 54
6.5 Oct 17, 2016: Syneron Medical Strengthens Senior Management Team 54

Access Report @ https://www.wiseguyreports.com/reports/729487-minimally-invasive-surgical-mis-devices-medical-devices-pipeline-assessment-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EINPresswire.com

Pharma Parallel Trade: Beyond Brexit and EU Falsified Medicine Directive

Parallel Trade 2017

SMi Group (2016.11.16 London) Over 90 senior leaders in parallel trade will meet in London in February 2017 to discuss upcoming trends and share best practices.

The best Parallel Trade conference of the last 5 years!

— Past Attendee of Parallel Trade 2016

LONDON, LONDON, UNITED KINGDOM, November 16, 2016 /EINPresswire.com/ — With Brexit and the new EU Falsified Medicine Directive, what does the future hold for parallel trade? SMi’s Parallel Trade conference will be returning to London next February 6th-7th, for its 11th year, to discuss short term and long term concerns of pharma manufacturers, regulators and parallel traders. They will engage in an interactive debate and discuss how to keep abreast of the current trends and how to overcome all challenges.

Parallel Trade 2017 official website is www.parallel-trade.com/EIN

Dr Rick Greville, Director Wales and Director Distribution & Supply for The Association of the British Pharmaceutical Industry will be speaking on “The European Commission's Falsified Medicines Directive – recent updates”. Dr. Gr0eville will discuss what progress has been made since February 2016 and what the market participants need to know about "product information templates", and much more.

Other key topics to be discussed during the 2-day conference are: What will Brexit mean for parallel trade to and from the UK? Parallel Trade 101 – Which factors determine the flow of pharmaceutical products in Europe? Beyond pharmaceutical products – parallel imports of medical devices. The Patient’s perspective.

The event programme also features three panel debates on: Shortages; Challenges and opportunities for parallel traders; Technology & new trends; and two exclusive post conference workshops on “Understanding IP and competition law issues in parallel trade” (Hosted by Kathy Osgerby, Associate and Karoline Zwierzynska, Associate, Arnold & Porter (UK) LLP) and “Parallel Trade – Management Strategies” (Hosted by Janice Haigh, Practice Leader, Market Access, Quintiles).

For further information please refer to www.parallel-trade.com/EIN

Expert Speakers Line up for 2017 includes: The Association of the British Pharmaceutical Industry (Dr Rick Greville, Director Distribution & Supply), Shire International GmbH (Eric Noehrenberg, Director, Regional Market Access Lead, Latin America), Delfarma (Tomasz Dzitko, President), European Association for Euro-Pharmaceutical Companies (Heinz Kobelt, Director European Affairs), ISPOR (Vladimir Zah, Health Economics Consultant), Abacus Medicine (Flemming Wagner, CEO), IMS Health (Alexey Savin, Principal Russia and CIS), Arnold & Porter (UK) LLP (Kathy Osgerby, Associate, and Karoline Zwierzynska, Associate), Europe Economics (Dermot Glynn, Senior Advisor), European Alliance for Access to Save Medicines (Mike Isles, Executive Director), Research Health (Dr Andrew Stainthorpe, Director Market Access and Managed Entry) and many more.

The complete 2-day event programme is available for complimentary download at www.parallel-trade.com/EIN
Latest confirmed attendees include senior representatives from Astellas Pharma, AstraZeneca, Teva UK, Vifor Pharma, Janssen Pharmaceutica NV, Napp Laboratories, Kantar Health, Ferring Pharmaceuticals, LEO Pharma, AstraZeneca Czech Republic, Swedish Orphan Biovitrum AB, Amgen, Novartis Pharmaceuticals, Novartis Turkey, LEO Pharma, Johnson & Johnson, Novo Nordisk Pharma, Daiichi Sankyo Europe GmbH, Sunovion Pharmaceuticals Europe Ltd and many more.
Feedback from past attendees of SMi Group’s Parallel Trade: “Interesting conference, generating a good debate from all sides”, “Great conference! Audience very enthusiastic and actively participating in discussions”, “Very good discussing about pricing issues and competition”, “Overall, a very positive experience!”, “The best Parallel Trade conference of the last 5 years!”.

11th annual Parallel Trade
6-7 February 2017, Holiday Inn Kensington Forum, London, UK
www.parallel-trade.com/EIN
Sponsorship, Exhibition contact: Alia Malick, +44 (0) 207 827 6168, amalick@smi-online.co.uk
Delegates/Group contact: Fateja Begum, +44 (0) 207 827 6184, fbegum@smi-online.co.uk
Media Contact: jrotar@smi-online.co.uk
______________________________end of press-release______________________
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Julia Rotar
SMi Group
2078276088
email us here

Source: EINPresswire.com

Nano Titanium Dioxide Market – Opportunities and Forecast 2016 – 2021

PUNE, INDIA, November 16, 2016 /EINPresswire.com/ — Nano Titanium Dioxide Market

This report studies Nano Titanium Dioxide in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
Sigma-Aldrich
US Research Nanomaterials, Inc.
Showa America
Gerhold Chemetals Co., Ltd
EPRUI Nanoparticles & Microspheres Co. Ltd
Green Earth Nano Science Inc.
Henan Huier Nano-Technology co.,Ltd
Xuan Cheng Jing Rui New Material Co.,Ltd
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Nano Titanium Dioxide in these regions, from 2011 to 2021 (forecast), like
North America
Europe
China
Japan
Southeast Asia
India

Request Sample Report @ https://www.wiseguyreports.com/sample-request/743254-global-nano-titanium-dioxide-market-research-report-2016

Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into
Type I
Type II
Type III
Split by application, this report focuses on consumption, market share and growth rate of Nano Titanium Dioxide in each application, can be divided into
Photocatalyst
Cosmetics
Automotive Topcoat
Other

Complete Report Details @ https://www.wiseguyreports.com/reports/743254-global-nano-titanium-dioxide-market-research-report-2016

Table of Contents

Global Nano Titanium Dioxide Market Research Report 2016
1 Nano Titanium Dioxide Market Overview
1.1 Product Overview and Scope of Nano Titanium Dioxide
1.2 Nano Titanium Dioxide Segment by Type
1.2.1 Global Production Market Share of Nano Titanium Dioxide by Type in 2015
1.2.2 Type I
1.2.3 Type II
1.2.4 Type III
1.3 Nano Titanium Dioxide Segment by Application
1.3.1 Nano Titanium Dioxide Consumption Market Share by Application in 2015
1.3.2 Photocatalyst
1.3.3 Cosmetics
1.3.4 Automotive Topcoat
1.3.5 Other
1.4 Nano Titanium Dioxide Market by Region
1.4.1 North America Status and Prospect (2011-2021)
1.4.2 Europe Status and Prospect (2011-2021)
1.4.3 China Status and Prospect (2011-2021)
1.4.4 Japan Status and Prospect (2011-2021)
1.4.5 Southeast Asia Status and Prospect (2011-2021)
1.4.6 India Status and Prospect (2011-2021)
1.5 Global Market Size (Value) of Nano Titanium Dioxide (2011-2021)

2 Global Nano Titanium Dioxide Market Competition by Manufacturers
2.1 Global Nano Titanium Dioxide Capacity, Production and Share by Manufacturers (2015 and 2016)
2.2 Global Nano Titanium Dioxide Revenue and Share by Manufacturers (2015 and 2016)
2.3 Global Nano Titanium Dioxide Average Price by Manufacturers (2015 and 2016)
2.4 Manufacturers Nano Titanium Dioxide Manufacturing Base Distribution, Sales Area and Product Type
2.5 Nano Titanium Dioxide Market Competitive Situation and Trends
2.5.1 Nano Titanium Dioxide Market Concentration Rate
2.5.2 Nano Titanium Dioxide Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Nano Titanium Dioxide Capacity, Production, Revenue (Value) by Region (2011-2016)
3.1 Global Nano Titanium Dioxide Capacity and Market Share by Region (2011-2016)
3.2 Global Nano Titanium Dioxide Production and Market Share by Region (2011-2016)
3.3 Global Nano Titanium Dioxide Revenue (Value) and Market Share by Region (2011-2016)
3.4 Global Nano Titanium Dioxide Capacity, Production, Revenue, Price and Gross Margin (2011-2016)
3.5 North America Nano Titanium Dioxide Capacity, Production, Revenue, Price and Gross Margin (2011-2016)
3.6 Europe Nano Titanium Dioxide Capacity, Production, Revenue, Price and Gross Margin (2011-2016)
3.7 China Nano Titanium Dioxide Capacity, Production, Revenue, Price and Gross Margin (2011-2016)
3.8 Japan Nano Titanium Dioxide Capacity, Production, Revenue, Price and Gross Margin (2011-2016)
3.9 Southeast Asia Nano Titanium Dioxide Capacity, Production, Revenue, Price and Gross Margin (2011-2016)
3.10 India Nano Titanium Dioxide Capacity, Production, Revenue, Price and Gross Margin (2011-2016)

4 Global Nano Titanium Dioxide Supply (Production), Consumption, Export, Import by Regions (2011-2016)
4.1 Global Nano Titanium Dioxide Consumption by Regions (2011-2016)
4.2 North America Nano Titanium Dioxide Production, Consumption, Export, Import by Regions (2011-2016)
4.3 Europe Nano Titanium Dioxide Production, Consumption, Export, Import by Regions (2011-2016)
4.4 China Nano Titanium Dioxide Production, Consumption, Export, Import by Regions (2011-2016)
4.5 Japan Nano Titanium Dioxide Production, Consumption, Export, Import by Regions (2011-2016)
4.6 Southeast Asia Nano Titanium Dioxide Production, Consumption, Export, Import by Regions (2011-2016)
4.7 India Nano Titanium Dioxide Production, Consumption, Export, Import by Regions (2011-2016)

5 Global Nano Titanium Dioxide Production, Revenue (Value), Price Trend by Type
5.1 Global Nano Titanium Dioxide Production and Market Share by Type (2011-2016)
5.2 Global Nano Titanium Dioxide Revenue and Market Share by Type (2011-2016)
5.3 Global Nano Titanium Dioxide Price by Type (2011-2016)
5.4 Global Nano Titanium Dioxide Production Growth by Type (2011-2016)

..……CONTINUED

For more information or any query mail at sales@wiseguyreports.com

Check Discount on This Report @ https://www.wiseguyreports.com/check-discount/743254-global-nano-titanium-dioxide-market-research-report-2016

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

ABOUT US:

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EINPresswire.com

MediPoint: Body Contouring – Global Analysis and Market Forecasts



Wise.Guy.

MediPoint: Body Contouring – Global Analysis and Market Forecasts

PUNE, INDIA, November 16, 2016 /EINPresswire.com/ — Body contouring devices are categorized into the following segments: minimally invasive body contouring devices and non-invasive body contouring devices.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/729484-medipoint-body-contouring-global-analysis-and-market-forecasts

Minimally invasive body contouring devices include –
– Laser-Assisted Liposuction Devices
– Radiofrequency Assisted Liposuction Devices
– Ultrasound Assisted Liposuction Devices
– Power Assisted Liposuction Devices

Non-invasive body contouring devices include –
– Radiofrequency Energy Devices
– High-Intensity Focused Ultrasound Devices
– Cryolipolysis Devices

Growth in the body contouring devices market is driven primarily by the growing non-invasive devices segment, an increasing global obesity rate, and the aging population.

The global market for body contouring devices is led by Syneron Candela, Cynosure, Solta Medical, and Zeltiq Aesthetics.

Key Questions Answered
– What are the unmet needs with the current generation of devices? Device Effectiveness? Device Efficiency?
– With developing the next-generation of devices, what aspects of the technology are device manufacturers focused on optimizing? How will new entrants impact the global body contouring device market?
– What trends and events are affecting the global market?
– Which are the key, high growth markets that device manufacturers should expand into? Which markets are growing the fastest, and what are the top-selling products?

Scope
– Competitive assessment: Currently marketed body contouring devices and evolving competitive landscape
– In-depth analysis of unmet needs and adoption trends of different body contouring devices
– Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
– Annualized total body contouring devices market revenue by segment and market outlooks by country from 2013-2022.
– Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global body contouring devices market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global body contouring devices market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track device sales in the global and country-specific body contouring devices market from 2013-2022.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 12
2 Introduction 14
2.1 Catalyst 14
2.2 Related Reports 15
3 Market Access 16
3.1 Reimbursement 16
3.2 Regulatory Issues/Recalls 16
3.3 Mergers and Acquisitions 17
3.3.1 The Lumenis Acquisition of Pollogen 18
3.3.2 The Valeant Acquisition of Solta Medical 18
3.3.3 The Cynosure Acquisition of Palomal Medical Technologies 18
3.3.4 The Fosun Acquisition of Alma Lasers 18
3.3.5 The Solta Medical Acquisition of Sound Surgical Technologies 18
4 Unmet Needs 19
4.1 Overview 19
4.2 Understanding of longterm outcomes for newer methods 19
4.3 Understanding the Clinical Outcomes of Combining Multiple Treatment Types 19
4.4 Clinical Measures of Procedure Effectiveness 19
4.5 Procedure Efficiency 20
4.6 Minimizing Post-Procedural Downtime 20
5 Competitive Assessment 21
5.1 Company Share Analysis 21
5.2 Major Players 22
5.2.1 Alma Lasers 22
5.2.2 Cutera 25
5.2.3 CynoSure 27
5.2.4 DEKA 29
5.2.5 Invasix Aesthetic Solutions 31
5.2.6 Lumenis 33
5.2.7 Syneron Candela 37
5.2.8 Solta Medical 39
5.2.9 Venus Concept 42
5.2.10 Zeltiq 44
6 Market Outlooks 47
6.1 Procedure Trends 47
6.2 Market Drivers and Barriers 48
6.2.1 Market Driver: Non-surgical Options 48
6.2.2 Market Driver: Men Getting More Cosmetic Surgery 49
6.2.3 Market Driver: Obesity 49
6.2.4 Market Driver: The Aging Population 49
6.2.5 Market Barrier: No Reimbursement 50
6.2.6 Market Barrier: Alternative Treatment Options 50
6.2.7 Market Barrier: Complications 51
6.2.8 Multiple Treatments Required 52
6.3 Market Outlooks by Segment 52
6.3.1 Minimally Invasive Body Contouring Devices 53
6.3.2 Non-invasive Body Contouring Devices 63
6.4 Market Outlooks by Geography 70
6.4.1 Global 70
6.4.2 Europe 72
6.4.3 Asia-Pacific 82
6.4.4 North America 91
6.4.5 South America 96
7 Appendix 98
7.1 Bibliography 98
7.2 Abbreviations 104
7.3 Methodology 105
7.4 Forecasting Methodology 106
7.4.1 Average Selling Prices 106
7.4.2 Market Segmentation 106
7.4.3 Company Share 106
7.5 Primary Research Efforts 107
7.6 About the Authors 108
7.6.1 Brigitte Babin, MSc, Analyst, Medical Devices 108
7.6.2 Linda Tian, MSc, Managing Analyst, Medical Devices 108

Access Report @ https://www.wiseguyreports.com/reports/729484-medipoint-body-contouring-global-analysis-and-market-forecasts

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EINPresswire.com

Sports Watches Market By Applications,Types,Regions And Companies Market Research Report To 2021



Wise.Guy.

PUNE, INDIA, November 16, 2016 /EINPresswire.com/ —

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/744091-global-sports-watches-market-research-report-2016

This report studies Sports Watches in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
CASIO
GARMIN
Suunto
Citizen
EZON
Nike
ADIDAS
Seiko
Fossil
Fitbit
SKMEI
Polar
Nike
EPSON
KAHUNA
LOTUS
TIMEX
Hanowa
Motorola
Apple
TomTom
SWISS EAGLE
NAUTICA

Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Sports Watches in these regions, from 2011 to 2021 (forecast), like
North America
Europe
China
Japan
Southeast Asia
India

Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into
Type I
Type II
Type III

Split by application, this report focuses on consumption, market share and growth rate of Sports Watches in each application, can be divided into
Application 1
Application 2
Application 3

Complete Report Details @ https://www.wiseguyreports.com/reports/744091-global-sports-watches-market-research-report-2016

Table of Contents

Global Sports Watches Market Research Report 2016

1 Sports Watches Market Overview
1.1 Product Overview and Scope of Sports Watches
1.2 Sports Watches Segment by Type
1.2.1 Global Production Market Share of Sports Watches by Type in 2015
1.2.2 Type I
1.2.3 Type II
1.2.4 Type III
1.3 Sports Watches Segment by Application
1.3.1 Sports Watches Consumption Market Share by Application in 2015
1.3.2 Application 1
1.3.3 Application 2
1.3.4 Application 3
1.4 Sports Watches Market by Region
1.4.1 North America Status and Prospect (2011-2021)
1.4.2 Europe Status and Prospect (2011-2021)
1.4.3 China Status and Prospect (2011-2021)
1.4.4 Japan Status and Prospect (2011-2021)
1.4.5 Southeast Asia Status and Prospect (2011-2021)
1.4.6 India Status and Prospect (2011-2021)
1.5 Global Market Size (Value) of Sports Watches (2011-2021)

2 Global Sports Watches Market Competition by Manufacturers
2.1 Global Sports Watches Production and Share by Manufacturers (2015 and 2016)
2.2 Global Sports Watches Revenue and Share by Manufacturers (2015 and 2016)
2.3 Global Sports Watches Average Price by Manufacturers (2015 and 2016)
2.4 Manufacturers Sports Watches Manufacturing Base Distribution, Sales Area and Product Type
2.5 Sports Watches Market Competitive Situation and Trends
2.5.1 Sports Watches Market Concentration Rate
2.5.2 Sports Watches Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Sports Watches Production, Revenue (Value) by Region (2011-2016)
3.1 Global Sports Watches Production by Region (2011-2016)
3.2 Global Sports Watches Production Market Share by Region (2011-2016)
3.3 Global Sports Watches Revenue (Value) and Market Share by Region (2011-2016)
3.4 Global Sports Watches Production, Revenue, Price and Gross Margin (2011-2016)
3.5 North America Sports Watches Production, Revenue, Price and Gross Margin (2011-2016)
3.6 Europe Sports Watches Production, Revenue, Price and Gross Margin (2011-2016)
3.7 China Sports Watches Production, Revenue, Price and Gross Margin (2011-2016)
3.8 Japan Sports Watches Production, Revenue, Price and Gross Margin (2011-2016)
3.9 Southeast Asia Sports Watches Production, Revenue, Price and Gross Margin (2011-2016)
3.10 India Sports Watches Production, Revenue, Price and Gross Margin (2011-2016)

4 Global Sports Watches Supply (Production), Consumption, Export, Import by Regions (2011-2016)
4.1 Global Sports Watches Consumption by Regions (2011-2016)
4.2 North America Sports Watches Production, Consumption, Export, Import by Regions (2011-2016)
4.3 Europe Sports Watches Production, Consumption, Export, Import by Regions (2011-2016)
4.4 China Sports Watches Production, Consumption, Export, Import by Regions (2011-2016)
4.5 Japan Sports Watches Production, Consumption, Export, Import by Regions (2011-2016)
4.6 Southeast Asia Sports Watches Production, Consumption, Export, Import by Regions (2011-2016)
4.7 India Sports Watches Production, Consumption, Export, Import by Regions (2011-2016)

……….

7 Global Sports Watches Manufacturers Profiles/Analysis
7.1 CASIO
7.1.1 Company Basic Information, Manufacturing Base and Its Competitors
7.1.2 Sports Watches Product Type, Application and Specification
7.1.2.1 Type I
7.1.2.2 Type II
7.1.3 CASIO Sports Watches Production, Revenue, Price and Gross Margin (2015 and 2016)
7.1.4 Main Business/Business Overview
7.2 GARMIN
7.2.1 Company Basic Information, Manufacturing Base and Its Competitors
7.2.2 Sports Watches Product Type, Application and Specification
7.2.2.1 Type I
7.2.2.2 Type II
7.2.3 GARMIN Sports Watches Production, Revenue, Price and Gross Margin (2015 and 2016)
7.2.4 Main Business/Business Overview
7.3 Suunto
7.3.1 Company Basic Information, Manufacturing Base and Its Competitors
7.3.2 Sports Watches Product Type, Application and Specification
7.3.2.1 Type I
7.3.2.2 Type II
7.3.3 Suunto Sports Watches Production, Revenue, Price and Gross Margin (2015 and 2016)
7.3.4 Main Business/Business Overview
7.4 Citizen
7.4.1 Company Basic Information, Manufacturing Base and Its Competitors
7.4.2 Sports Watches Product Type, Application and Specification
7.4.2.1 Type I
7.4.2.2 Type II

…..Continued

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=744091

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EINPresswire.com

Pancreatic Cancer Market Global Industry Analysis 2016

“Pancreatic Cancer -Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs across this indication

PUNE, INDIA , November 16, 2016 /EINPresswire.com/ — Global Pancreatic Cancer Market

Summary

DelveInsight’s, “Pancreatic Cancer -Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all 103 pipeline drugs that fall under the category of Pancreatic Cancer.
Recent report of Delveinsight covers drugs that are being developed with novel approach to target or intervene along the pathways of tumorigenesis. Among the pipeline agents NewLink Genetics Corporation’s algenpantucel-L is expected to be the frontrunner amongst all other drugs. The therapeutic candidate has also received fast Track and orphan drug designations from the FDA and is expected to launch in both the resectable and unresectable locally-advanced settings.
The report also provides a comparative analysis of therapeutics based on the molecule type, route of administration, etc. It also gives insights of other activities such as, agreements, joint ventures, partnerships, acquisitions and mergers.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/476527-pancreatic-cancer-pipeline-insights-2016

Scope:

The new report, provides a Pancreatic Cancer Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
• Coverage of the Pancreatic Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Pancreatic Cancer and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Access Complete Report @ https://www.wiseguyreports.com/reports/476527-pancreatic-cancer-pipeline-insights-2016

Reasons to Buy

Complete Pipeline intelligence and complete understanding over therapeutics development for Pancreatic Cancer
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents:

Pancreatic Cancer Overview
• Pancreatic Cancer Types:
• Epidemiology:
• Market Scenario:
• Pipeline Therapeutics
• An Overview of Pipeline Products for Pancreatic Cancer
• Therapeutics under Development by Companies
• Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Mid Stage Products (Phase II)
• Comparative Analysis
• Early Stage Products (Phase I and IND)
• Comparative Analysis
• Discovery and Pre-clinical stage Products
• Comparative Analysis
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Discontinued Products
• Dormant Products
• Companies involved in Therapeutics Development
• Appendix
• Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
• Contact Us
List of Tables:

Table 1: Number of Products Under Development for Pancreatic Cancer 2016
• Table 2: Number of Products under Development by Companies, 2016
• Table 3: Last Stage Products (Phase III and Filed), 2016
• Table 4: Mid Stage Products (Phase II), 2016
• Table 5: Early Stage Products (Phase I and IND), 2016
• Table 6: Phase 0 stage Products, 2016
• Table 7: Discovery and Pre-clinical Stage Products, 2016
• Table 8: Assessment by Monotherapy Products, 2016
• Table 9: Assessment by Route Of Administration, 2016
• Table 10: Assessment by Stage and Route Of Administration, 2016
• Table 11: Assessment by Molecule Type, 2016
• Table 12: Assessment by Stage and Molecule Type, 2016
• Table 13: Discontinued Products, 2016
• Table 14: Dormant Products, 2016
• Table 15: Companies Involved in Therapeutic Development, 2016
List of Figures:

Figure 1: Number of Products under Development for Pancreatic Cancer, 2016
• Figure 2: Late Stage Products (Filed and Phase III), 2016
• Figure 3: Mid Stage Products (Phase II), 2016
• Figure 4: Early Stage Products (Phase I and IND), 2016
• Figure 5: Discovery and Pre-clinical Stage Products, 2016
• Figure 6: Assessment by Monotherapy Products, 2016
• Figure 7: Assessment by Combination Products, 2016
• Figure 8: Assessment by Route of Administration, 2016
• Figure 9: Assessment by Stage and Route of Administration, 2016
• Figure 10: Assessment by Molecule Type, 2016
• Figure 11: Assessment by Stage and Molecule Type, 2016
Buy Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=476527

For more information or any query mail at sales@wiseguyreports.com

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EINPresswire.com

Germany Power Market Outlook to 2030, Update 2016: Market Trends, Regulations, and Competitive Landscape



Wise.Guy.

Germany Power Market Outlook to 2030, Update 2016 Market Trends, Regulations, and Competitive Landscape

PUNE, INDIA, November 16, 2016 /EINPresswire.com/ — This report elaborates Germany's power market structure and provides historical and forecast numbers for capacity, generation, and consumption up to 2030. Detailed analysis of the Germany power market’s regulatory structure, import and export trends, competitive landscape, and power projects at various stages of the supply chain is provided. The report also gives a snapshot of the power sector in Germany on broad parameters of macroeconomics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario, and future potential. Financial performance of the leading power companies is also analyzed in the report.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/729541-germany-power-market-outlook-and-competitive-landscape

Scope
– Snapshot of the country’s power sector across parameters – macro economics, supply security, generation infrastructure, transmission infrastructure, degree of competition, regulatory scenario and future potential of the power sector.
– Statistics for installed capacity, power generation and consumption from 2000 to 2015, forecast for the next 15 years to 2030.
– Break-up by technology, including thermal, hydro, renewable and nuclear
– Data on leading current and upcoming projects.
– Information on grid interconnectivity, transmission and distribution infrastructure and power exports and imports.
– Policy and regulatory framework governing the market.
– Detailed analysis of top market participant, including market share analysis and SWOT analysis.

Reasons to buy
– Identify opportunities and plan strategies by having a strong understanding of the investment opportunities in the country’s power sector
– Identification of key factors driving investment opportunities in the country’s power sector
– Facilitate decision-making based on strong historic and forecast data
– Develop strategies based on the latest regulatory events
– Position yourself to gain the maximum advantage of the industry’s growth potential
– Identify key partners and business development avenues
– Identify key strengths and weaknesses of important market participants
– Respond to your competitors’ business structure, strategy and prospects.

Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 GlobalData Report Guidance 11
3 Germany, Power Market, Snapshot 12
3.1 Germany, Power Market, Macroeconomic Factors 12
3.2 Germany, Power Market, Supply Security 14
3.3 Germany, Power Market, Opportunities 15
3.4 Germany, Power Market, Challenges 15
4 Germany, Power Market, Market Analysis 17
4.1 Germany, Power Market, Supply Structure 17
4.2 Germany, Power Market, Key Market Players 17
4.3 Germany, Power Market, Financial Deals 18
4.3.1 Deal Volume and Value Analysis, 2004-August 2016 18
4.3.2 Deals by Type, 2015 20
4.4 Germany, Power Market, Demand Structure 21
4.4.1 Germany, Consumption by Sector, 2015 23
5 Germany, Power Market, Regulatory Scenario 24
5.1 Germany, Power Market, Key Electricity Policies 24
5.1.1 Amendment of German Act against Restraints on Competition 25
5.1.2 Amendment of German Energy Act 26
5.1.3 Large Combustion Plant Directive 26
5.1.4 Amendment of German Greenhouse Gas Emission Trading Law 27
5.1.5 Target Grid 2050 27
5.1.6 Renewable Energy Policies 28
5.1.7 Subsidy for Solar Photovoltaic with Storage Installations 29
5.1.8 Nuclear Energy Policies 29
5.1.9 Initiatives to Reduce Greenhouse and Carbon Dioxide Emissions 30
6 Germany, Power Market, Capacity and Generation Overview 31
6.1 Germany, Power Market, Cumulative Installed Capacity, by Fuel Type, 2015 31
6.2 Germany, Power Market, Cumulative Installed Capacity and Annual Power Generation, 2000-2030 32
6.2.1 Cumulative Installed Thermal Capacity and Annual Thermal Power Generation, 2000-2030 35
6.2.2 Cumulative Installed Hydropower Capacity and Annual Hydropower Generation, 2000-2030 39
6.2.3 Cumulative Installed Nuclear Capacity and Annual Nuclear Power Generation, 2000-2030 43
6.2.4 Cumulative Installed Non-hydro Renewable Capacity and Annual Non-hydro Renewable Power Generation, 2000-2030 46
7 Germany, Power Market, Transmission and Distribution Overview 50
7.1 Germany, Power Market, Transmission Overview 50
7.2 Germany, Power Market, Distribution Overview 51
7.3 Germany, Power Market, Grid Interconnection 52
7.3.1 Electricity Import and Export Trends, 2000-2015 54
7.4 Germany, Power Market, Electricity Trading 55
8 Germany, Power Market, Competitive Landscape: Snapshot of Leading Power Generation Companies 56
8.1 Key Company in the Germany Power Market – RWE AG 56
8.1.1 Business Description 56
8.1.2 SWOT Overview 57
8.2 Key Company in the Germany Power Market – E.ON SE 60
8.2.1 Company Overview 60
8.2.2 Business Description 60
8.2.3 SWOT Overview 61
8.3 Key Company in the Germany Power Market – Vattenfall AB 64
8.3.1 Company Overview 64
8.3.2 Business Description 64
8.3.3 SWOT Overview 65
8.4 Key Company in the Germany Power Market – EnBW 68
8.4.1 Company Overview 68
8.4.2 Business Description 68
8.4.3 SWOT Overview 70

Access Report @ https://www.wiseguyreports.com/reports/729541-germany-power-market-outlook-and-competitive-landscape

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EINPresswire.com

Vagus Nerve Stimulators: Medical Devices Pipeline Assessment 2016



Wise.Guy.

Vagus Nerve Stimulators Medical Devices Pipeline Assessment, 2016

PUNE, INDIA, November 16, 2016 /EINPresswire.com/ — The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vagus Nerve Stimulators pipeline products.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/729489-vagus-nerve-stimulators-medical-devices-pipeline-assessment-2016

This report is prepared using data sourced from in-house databases, secondary and primary research by team of industry experts.

Scope
– Extensive coverage of the Vagus Nerve Stimulators under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of Vagus Nerve Stimulators and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment / industry

The report enables you to –
– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of Vagus Nerve Stimulators under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Vagus Nerve Stimulators Overview 7
3 Products under Development 8
3.1 Vagus Nerve Stimulators – Pipeline Products by Stage of Development 8
3.2 Vagus Nerve Stimulators – Pipeline Products by Territory 9
3.3 Vagus Nerve Stimulators – Pipeline Products by Regulatory Path 10
3.4 Vagus Nerve Stimulators – Pipeline Products by Estimated Approval Date 11
3.5 Vagus Nerve Stimulators – Ongoing Clinical Trials 12
4 Vagus Nerve Stimulators – Pipeline Products under Development by Companies 13
4.1 Vagus Nerve Stimulators Companies – Pipeline Products by Stage of Development 13
4.2 Vagus Nerve Stimulators – Pipeline Products by Stage of Development 14
5 Vagus Nerve Stimulators Companies and Product Overview 15
5.1 BioControl Medical Company Overview 15
5.1.1 BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview 15
5.2 Boston Scientific Corporation Company Overview 17
5.2.1 Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 17
5.3 CerboMed GmbH Company Overview 21
5.3.1 CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview 21
5.4 Cerebral RX Ltd. Company Overview 22
5.4.1 Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22
5.5 Cyberonics, Inc. Company Overview 23
5.5.1 Cyberonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23
5.6 DuoCure Ltd. Company Overview 27
5.6.1 DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview 27
5.7 ElectroCore, LLC Company Overview 28
5.7.1 ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview 28
5.8 LivaNova PLC Company Overview 34
5.8.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 34
5.9 Medical University of South Carolina Company Overview 40
5.9.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 40
5.10 MicroTransponder Inc. Company Overview 42
5.10.1 MicroTransponder Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
5.11 Neurostream Technologies G.P. (Inactive) Company Overview 49
5.11.1 Neurostream Technologies G.P. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 49
5.12 Purdue University Company Overview 51
5.12.1 Purdue University Pipeline Products & Ongoing Clinical Trials Overview 51
5.13 Setpoint Medical Corp Company Overview 52
5.13.1 Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 52
5.14 Trifectas Medical Corp. Company Overview 56
5.14.1 Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 56
6 Vagus Nerve Stimulators- Recent Developments 57
6.1 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 57
6.2 Oct 19, 2016: SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease 58

Access Report @ https://www.wiseguyreports.com/reports/729489-vagus-nerve-stimulators-medical-devices-pipeline-assessment-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EINPresswire.com

Cerebro Spinal Fluid Management : Medical Devices Pipeline Assessment 2016



Wise.Guy.

Cerebro Spinal Fluid Management – Health and Medical Devices Pipeline Assessment, 2016

PUNE, INDIA, November 16, 2016 /EINPresswire.com/ — The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cerebro Spinal Fluid Management pipeline products.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/729486-cerebro-spinal-fluid-management-medical-devices-pipeline-assessment-2016

This report is prepared using data sourced from in-house databases, secondary and primary research by team of industry experts.

Scope
– Extensive coverage of the Cerebro Spinal Fluid Management under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of Cerebro Spinal Fluid Management and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment / industry

The report enables you to –
– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of Cerebro Spinal Fluid Management under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 CSF Management Overview 8
3 Products under Development 9
3.1 Cerebro Spinal Fluid Management – Pipeline Products by Stage of Development 9
3.2 Cerebro Spinal Fluid Management – Pipeline Products by Segment 10
3.3 Cerebro Spinal Fluid Management – Pipeline Products by Territory 11
3.4 Cerebro Spinal Fluid Management – Pipeline Products by Regulatory Path 12
3.5 Cerebro Spinal Fluid Management – Pipeline Products by Estimated Approval Date 13
3.6 Cerebro Spinal Fluid Management – Ongoing Clinical Trials 14
4 Cerebro Spinal Fluid Management – Pipeline Products under Development by Companies 15
4.1 Cerebro Spinal Fluid Management Companies – Pipeline Products by Stage of Development 15
4.2 Cerebro Spinal Fluid Management – Pipeline Products by Stage of Development 17
5 Cerebro Spinal Fluid Management Companies and Product Overview 19
5.1 Alcyone Lifesciences, Inc. Company Overview 19
5.1.1 Alcyone Lifesciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
5.2 Aqueduct Neurosciences Company Overview 22
5.2.1 Aqueduct Neurosciences Pipeline Products & Ongoing Clinical Trials Overview 22
5.3 Arkis BioSciences Company Overview 24
5.3.1 Arkis BioSciences Pipeline Products & Ongoing Clinical Trials Overview 24
5.4 Beckersmith Medical, Inc. Company Overview 25
5.4.1 Beckersmith Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25
5.5 Biosan Medical Ltd. Company Overview 26
5.5.1 Biosan Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 26
5.6 Georgia Institute of Technology Company Overview 28
5.6.1 Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 28
5.7 H-Cubed Inc. Company Overview 30
5.7.1 H-Cubed Inc. Pipeline Products & Ongoing Clinical Trials Overview 30
5.8 Integra LifeSciences Holdings Corporation Company Overview 31
5.8.1 Integra LifeSciences Holdings Corporation Pipeline Products & Ongoing Clinical Trials Overview 31
5.9 InVivo Therapeutics Corporation Company Overview 35
5.9.1 InVivo Therapeutics Corporation Pipeline Products & Ongoing Clinical Trials Overview 35
5.10 Kerecis ehf Company Overview 38
5.10.1 Kerecis ehf Pipeline Products & Ongoing Clinical Trials Overview 38
5.11 Microbot Medical, Ltd. Company Overview 39
5.11.1 Microbot Medical, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 39
5.12 Nanonerve Inc. Company Overview 41
5.12.1 Nanonerve Inc. Pipeline Products & Ongoing Clinical Trials Overview 41
5.13 NeuraMedica, LLC Company Overview 42
5.13.1 NeuraMedica, LLC Pipeline Products & Ongoing Clinical Trials Overview 42
5.14 NexGen Medical Systems, Inc. Company Overview 43
5.14.1 NexGen Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
5.15 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 44
5.15.1 Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview 44
5.16 System Science Inc. Company Overview 46
5.16.1 System Science Inc. Pipeline Products & Ongoing Clinical Trials Overview 46
5.17 University Hospital Zurich Company Overview 48
5.17.1 University Hospital Zurich Pipeline Products & Ongoing Clinical Trials Overview 48
5.18 University of Rochester Company Overview 50
5.18.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 50
5.19 University of South Florida Company Overview 51
5.19.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 51
5.20 University of Wisconsin Madison Company Overview 53
5.20.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 53
5.21 Vivonics, Inc. Company Overview 55
5.21.1 Vivonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 55
5.22 Wayne State University Company Overview 57
5.22.1 Wayne State University Pipeline Products & Ongoing Clinical Trials Overview 57
6 Cerebro Spinal Fluid Management- Recent Developments 59
6.1 Oct 26, 2016: LeMaitre Q3 2016 Record Sales $23.2 mm (+22%), Record Op. Income $5.3 mm (+61%) 59
6.2 Oct 12, 2016: HyperBranch Medical Wins Decision Against Integra Lifesciences 59
6.3 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 60
6.4 Aug 31, 2016: Cook Medical Names Jean-Marc Creissel Vice President of Operations in Greater China 61
6.5 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 61

Access Report @ https://www.wiseguyreports.com/reports/729486-cerebro-spinal-fluid-management-medical-devices-pipeline-assessment-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EINPresswire.com

Cardiovascular Imaging Equipment Therapeutic and Overview Pipeline Review H2



Wise.Guy.

Cardiovascular Imaging Equipment Treatment Pipeline Review H2 2016

PUNE, INDIA, November 16, 2016 /EINPresswire.com/ — The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiovascular Imaging Equipment pipeline products.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/729485-cardiovascular-imaging-equipment-medical-devices-pipeline-assessment-2016

Scope
– Extensive coverage of the Cardiovascular Imaging Equipment under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of Cardiovascular Imaging Equipment and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment / industry

The report enables you to –
– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of Cardiovascular Imaging Equipment under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Cardiovascular Imaging Equipment Overview 7
3 Products under Development 8
3.1 Cardiovascular Imaging Equipment – Pipeline Products by Stage of Development 8
3.2 Cardiovascular Imaging Equipment – Pipeline Products by Territory 9
3.3 Cardiovascular Imaging Equipment – Pipeline Products by Regulatory Path 10
3.4 Cardiovascular Imaging Equipment – Pipeline Products by Estimated Approval Date 11
4 Cardiovascular Imaging Equipment – Pipeline Products under Development by Companies 12
4.1 Cardiovascular Imaging Equipment Companies – Pipeline Products by Stage of Development 12
4.2 Cardiovascular Imaging Equipment – Pipeline Products by Stage of Development 13
5 Cardiovascular Imaging Equipment Companies and Product Overview 14
5.1 Arineta Ltd. Company Overview 14
5.1.1 Arineta Ltd. Pipeline Products & Ongoing Clinical Trials Overview 14
5.2 Beth Israel Deaconess Medical Center, Inc. Company Overview 15
5.2.1 Beth Israel Deaconess Medical Center, Inc. Pipeline Products & Ongoing Clinical Trials Overview 15
5.3 CardioPaint Company Overview 16
5.3.1 CardioPaint Pipeline Products & Ongoing Clinical Trials Overview 16
5.4 Evena Medical, Inc. Company Overview 17
5.4.1 Evena Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 17
5.5 FMI Technologies, Inc. Company Overview 18
5.5.1 FMI Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18
5.6 GE Healthcare Limited Company Overview 19
5.6.1 GE Healthcare Limited Pipeline Products & Ongoing Clinical Trials Overview 19
5.7 Illumasonix LLC Company Overview 21
5.7.1 Illumasonix LLC Pipeline Products & Ongoing Clinical Trials Overview 21
5.8 King's College London Company Overview 22
5.8.1 King's College London Pipeline Products & Ongoing Clinical Trials Overview 22
5.9 Medistim ASA Company Overview 23
5.9.1 Medistim ASA Pipeline Products & Ongoing Clinical Trials Overview 23
5.10 Nano4Imaging GmbH Company Overview 26
5.10.1 Nano4Imaging GmbH Pipeline Products & Ongoing Clinical Trials Overview 26
5.11 Perinatronics Medical systems Inc Company Overview 27
5.11.1 Perinatronics Medical systems Inc Pipeline Products & Ongoing Clinical Trials Overview 27
5.12 Purdue University Company Overview 28
5.12.1 Purdue University Pipeline Products & Ongoing Clinical Trials Overview 28
5.13 University of Colorado Company Overview 29
5.13.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 29
5.14 Volcano Corporation Company Overview 30
5.14.1 Volcano Corporation Pipeline Products & Ongoing Clinical Trials Overview 30
5.15 Wisconsin Institute of Nuclear Systems Company Overview 37
5.15.1 Wisconsin Institute of Nuclear Systems Pipeline Products & Ongoing Clinical Trials Overview 37
6 Cardiovascular Imaging Equipment- Recent Developments 39
6.1 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 39
6.2 Oct 26, 2016: LeMaitre Q3 2016 Record Sales $23.2 mm (+22%), Record Op. Income $5.3 mm (+61%) 40
6.3 Oct 24, 2016: St. Jude Medical Announces Data to be Presented as Late-Breaking Clinical Trials and Highlights Its Latest Cardiovascular Portfolio at the 2016 TCT Conference 41
6.4 Oct 20, 2016: Medistim: Results for the Third Quarter 2016 42
6.5 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 43
6.6 Oct 18, 2016: FluoroPharma Medical Enters into Partnership with Koninklijke Philips 45
6.7 Oct 11, 2016: LiDCO GROUP: Interim Results for the six months ended 31 July 2016 45
6.8 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 49
6.9 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 50
6.10 Sep 08, 2016: Lantheus Holdings Prices Public Offering of Shares For USD40 Million 50
6.11 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 51
6.12 Aug 24, 2016: Medistim: 2nd quarter and 1st half report for 2016 53
6.13 Aug 23, 2016: Philips showcases full suite of cardiology solutions for personalized approach to prevention, diagnosis and treatment of cardiovascular disease at ESC Congress 2016 57
6.14 Aug 10, 2016: Arineta CT FDA Clearance 58
6.15 Aug 09, 2016: Stereotaxis Reports 2016 Second Quarter Financial Results 59

Access Report @ https://www.wiseguyreports.com/reports/729485-cardiovascular-imaging-equipment-medical-devices-pipeline-assessment-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EINPresswire.com